Proliferative Diabetic Retinopathy Market - Global Outlook and Forecast 2022-2028

March 2022 | 65 pages | ID: P4D625FA192DEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Proliferative Diabetic Retinopathy in Global, including the following market information:

Global Proliferative Diabetic Retinopathy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Proliferative Diabetic Retinopathy market was valued at 454.7 million in 2021 and is projected to reach US$ 647 million by 2028, at a CAGR of 5.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Anti-VEGF Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Proliferative Diabetic Retinopathy include Intas Pharmaceuticals, Santen Pharmaceutical, Bausch Health, Allergan Plc, Regeneron Pharmaceuticals, Merck KGaA, Cipla, Genentech, Inc. (Roche Holdings) and Novartis and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Proliferative Diabetic Retinopathy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Proliferative Diabetic Retinopathy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Proliferative Diabetic Retinopathy Market Segment Percentages, by Type, 2021 (%)

• Anti-VEGF Agents
• Corticosteroids

Global Proliferative Diabetic Retinopathy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Proliferative Diabetic Retinopathy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Others

Global Proliferative Diabetic Retinopathy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Proliferative Diabetic Retinopathy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Proliferative Diabetic Retinopathy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Proliferative Diabetic Retinopathy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Intas Pharmaceuticals
• Santen Pharmaceutical
• Bausch Health
• Allergan Plc
• Regeneron Pharmaceuticals
• Merck KGaA
• Cipla
• Genentech, Inc. (Roche Holdings)
• Novartis
• Pfizer

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Proliferative Diabetic Retinopathy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Proliferative Diabetic Retinopathy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY OVERALL MARKET SIZE

2.1 Global Proliferative Diabetic Retinopathy Market Size: 2021 VS 2028
2.2 Global Proliferative Diabetic Retinopathy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Proliferative Diabetic Retinopathy Players in Global Market
3.2 Top Global Proliferative Diabetic Retinopathy Companies Ranked by Revenue
3.3 Global Proliferative Diabetic Retinopathy Revenue by Companies
3.4 Top 3 and Top 5 Proliferative Diabetic Retinopathy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Proliferative Diabetic Retinopathy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Proliferative Diabetic Retinopathy Players in Global Market
  3.6.1 List of Global Tier 1 Proliferative Diabetic Retinopathy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Proliferative Diabetic Retinopathy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Proliferative Diabetic Retinopathy Market Size Markets, 2021 & 2028
  4.1.2 Anti-VEGF Agents
  4.1.3 Corticosteroids
4.2 By Type - Global Proliferative Diabetic Retinopathy Revenue & Forecasts
  4.2.1 By Type - Global Proliferative Diabetic Retinopathy Revenue, 2017-2022
  4.2.2 By Type - Global Proliferative Diabetic Retinopathy Revenue, 2023-2028
  4.2.3 By Type - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Proliferative Diabetic Retinopathy Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Others
5.2 By Application - Global Proliferative Diabetic Retinopathy Revenue & Forecasts
  5.2.1 By Application - Global Proliferative Diabetic Retinopathy Revenue, 2017-2022
  5.2.2 By Application - Global Proliferative Diabetic Retinopathy Revenue, 2023-2028
  5.2.3 By Application - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Proliferative Diabetic Retinopathy Market Size, 2021 & 2028
6.2 By Region - Global Proliferative Diabetic Retinopathy Revenue & Forecasts
  6.2.1 By Region - Global Proliferative Diabetic Retinopathy Revenue, 2017-2022
  6.2.2 By Region - Global Proliferative Diabetic Retinopathy Revenue, 2023-2028
  6.2.3 By Region - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Proliferative Diabetic Retinopathy Revenue, 2017-2028
  6.3.2 US Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.3.3 Canada Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.3.4 Mexico Proliferative Diabetic Retinopathy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Proliferative Diabetic Retinopathy Revenue, 2017-2028
  6.4.2 Germany Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.3 France Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.4 U.K. Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.5 Italy Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.6 Russia Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.7 Nordic Countries Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.4.8 Benelux Proliferative Diabetic Retinopathy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Proliferative Diabetic Retinopathy Revenue, 2017-2028
  6.5.2 China Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.5.3 Japan Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.5.4 South Korea Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.5.5 Southeast Asia Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.5.6 India Proliferative Diabetic Retinopathy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Proliferative Diabetic Retinopathy Revenue, 2017-2028
  6.6.2 Brazil Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.6.3 Argentina Proliferative Diabetic Retinopathy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Proliferative Diabetic Retinopathy Revenue, 2017-2028
  6.7.2 Turkey Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.7.3 Israel Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.7.4 Saudi Arabia Proliferative Diabetic Retinopathy Market Size, 2017-2028
  6.7.5 UAE Proliferative Diabetic Retinopathy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Intas Pharmaceuticals
  7.1.1 Intas Pharmaceuticals Corporate Summary
  7.1.2 Intas Pharmaceuticals Business Overview
  7.1.3 Intas Pharmaceuticals Proliferative Diabetic Retinopathy Major Product Offerings
  7.1.4 Intas Pharmaceuticals Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.1.5 Intas Pharmaceuticals Key News
7.2 Santen Pharmaceutical
  7.2.1 Santen Pharmaceutical Corporate Summary
  7.2.2 Santen Pharmaceutical Business Overview
  7.2.3 Santen Pharmaceutical Proliferative Diabetic Retinopathy Major Product Offerings
  7.2.4 Santen Pharmaceutical Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.2.5 Santen Pharmaceutical Key News
7.3 Bausch Health
  7.3.1 Bausch Health Corporate Summary
  7.3.2 Bausch Health Business Overview
  7.3.3 Bausch Health Proliferative Diabetic Retinopathy Major Product Offerings
  7.3.4 Bausch Health Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.3.5 Bausch Health Key News
7.4 Allergan Plc
  7.4.1 Allergan Plc Corporate Summary
  7.4.2 Allergan Plc Business Overview
  7.4.3 Allergan Plc Proliferative Diabetic Retinopathy Major Product Offerings
  7.4.4 Allergan Plc Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.4.5 Allergan Plc Key News
7.5 Regeneron Pharmaceuticals
  7.5.1 Regeneron Pharmaceuticals Corporate Summary
  7.5.2 Regeneron Pharmaceuticals Business Overview
  7.5.3 Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Major Product Offerings
  7.5.4 Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.5.5 Regeneron Pharmaceuticals Key News
7.6 Merck KGaA
  7.6.1 Merck KGaA Corporate Summary
  7.6.2 Merck KGaA Business Overview
  7.6.3 Merck KGaA Proliferative Diabetic Retinopathy Major Product Offerings
  7.6.4 Merck KGaA Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.6.5 Merck KGaA Key News
7.7 Cipla
  7.7.1 Cipla Corporate Summary
  7.7.2 Cipla Business Overview
  7.7.3 Cipla Proliferative Diabetic Retinopathy Major Product Offerings
  7.7.4 Cipla Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.7.5 Cipla Key News
7.8 Genentech, Inc. (Roche Holdings)
  7.8.1 Genentech, Inc. (Roche Holdings) Corporate Summary
  7.8.2 Genentech, Inc. (Roche Holdings) Business Overview
  7.8.3 Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Major Product Offerings
  7.8.4 Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.8.5 Genentech, Inc. (Roche Holdings) Key News
7.9 Novartis
  7.9.1 Novartis Corporate Summary
  7.9.2 Novartis Business Overview
  7.9.3 Novartis Proliferative Diabetic Retinopathy Major Product Offerings
  7.9.4 Novartis Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.9.5 Novartis Key News
7.10 Pfizer
  7.10.1 Pfizer Corporate Summary
  7.10.2 Pfizer Business Overview
  7.10.3 Pfizer Proliferative Diabetic Retinopathy Major Product Offerings
  7.10.4 Pfizer Proliferative Diabetic Retinopathy Revenue in Global Market (2017-2022)
  7.10.5 Pfizer Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Proliferative Diabetic Retinopathy Market Opportunities & Trends in Global Market
Table 2. Proliferative Diabetic Retinopathy Market Drivers in Global Market
Table 3. Proliferative Diabetic Retinopathy Market Restraints in Global Market
Table 4. Key Players of Proliferative Diabetic Retinopathy in Global Market
Table 5. Top Proliferative Diabetic Retinopathy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Proliferative Diabetic Retinopathy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Proliferative Diabetic Retinopathy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Proliferative Diabetic Retinopathy Product Type
Table 9. List of Global Tier 1 Proliferative Diabetic Retinopathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Proliferative Diabetic Retinopathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Proliferative Diabetic Retinopathy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Proliferative Diabetic Retinopathy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Proliferative Diabetic Retinopathy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Proliferative Diabetic Retinopathy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Proliferative Diabetic Retinopathy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Proliferative Diabetic Retinopathy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2023-2028
Table 30. Intas Pharmaceuticals Corporate Summary
Table 31. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Product Offerings
Table 32. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 33. Santen Pharmaceutical Corporate Summary
Table 34. Santen Pharmaceutical Proliferative Diabetic Retinopathy Product Offerings
Table 35. Santen Pharmaceutical Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 36. Bausch Health Corporate Summary
Table 37. Bausch Health Proliferative Diabetic Retinopathy Product Offerings
Table 38. Bausch Health Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 39. Allergan Plc Corporate Summary
Table 40. Allergan Plc Proliferative Diabetic Retinopathy Product Offerings
Table 41. Allergan Plc Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 42. Regeneron Pharmaceuticals Corporate Summary
Table 43. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Product Offerings
Table 44. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 45. Merck KGaA Corporate Summary
Table 46. Merck KGaA Proliferative Diabetic Retinopathy Product Offerings
Table 47. Merck KGaA Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 48. Cipla Corporate Summary
Table 49. Cipla Proliferative Diabetic Retinopathy Product Offerings
Table 50. Cipla Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 51. Genentech, Inc. (Roche Holdings) Corporate Summary
Table 52. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Product Offerings
Table 53. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 54. Novartis Corporate Summary
Table 55. Novartis Proliferative Diabetic Retinopathy Product Offerings
Table 56. Novartis Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)
Table 57. Pfizer Corporate Summary
Table 58. Pfizer Proliferative Diabetic Retinopathy Product Offerings
Table 59. Pfizer Proliferative Diabetic Retinopathy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Proliferative Diabetic Retinopathy Segment by Type in 2021
Figure 2. Proliferative Diabetic Retinopathy Segment by Application in 2021
Figure 3. Global Proliferative Diabetic Retinopathy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Proliferative Diabetic Retinopathy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Proliferative Diabetic Retinopathy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Proliferative Diabetic Retinopathy Revenue in 2021
Figure 8. By Type - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 12. US Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 16. Germany Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 17. France Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 24. China Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 28. India Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 30. Brazil Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Proliferative Diabetic Retinopathy Revenue Market Share, 2017-2028
Figure 33. Turkey Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Proliferative Diabetic Retinopathy Revenue, (US$, Mn), 2017-2028
Figure 37. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Santen Pharmaceutical Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bausch Health Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Allergan Plc Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck KGaA Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Cipla Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Novartis Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Pfizer Proliferative Diabetic Retinopathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)